Certain BCG-reactive responses are associated with bladder cancer prognosis

Cancer Immunology, Immunotherapy : CII
Guang ShanYue Xia

Abstract

A subset of bladder patients does not respond to BCG treatment effectively and the underlying reason behind this observation is currently unclear. CD4+ T cells are composed of various subsets that each expresses a distinctive set of cytokines and can potently shift the immune response toward various directions. In this study, we examined the CD4+ T-cell cytokine response in bladder cancer patients toward BCG stimulation. We found that bladder cancer patients presented a variety of responses toward BCG, with no uniform characteristics. Those patients with high IFN-γ and IL-21 expression in CD4+ T cells presented significantly better prognosis than patients with low cytokine secretion in CD4+ T cells. Tumor-infiltrating CD4+ T cells were significantly less potent in expressing IFN-γ, IL-4, and IL-17, and more potent in expressing IL-10 than circulating CD4+ T cells. In addition, we found no difference in CD80, CD86, or MHC II expression by macrophages from patients with different IFN-γ and IL-21 levels. However, the secretion of IL-12, a Th1-skewing cytokine, was released at significantly higher level by macrophages from patients with high IFN-γ or high IL-21 secretion. We also identified that modulating monocytes/macrophages by ...Continue Reading

References

Dec 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Veronica Athie-MoralesCatharien M U Hilkens
Dec 22, 2006·Expert Review of Anticancer Therapy·David Y JosephsonJohn P Stein
Oct 6, 2007·Immunologic Research·Mark P SimonsThomas S Griffith
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ian D DavisPallavur V Sivakumar
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary L Disis
Jul 20, 2010·Immunotherapy·Anton B AlexandroffAndrew M Jackson
Feb 12, 2011·Current Opinion in Infectious Diseases·Jean-Louis MègeChristian Capo
Feb 15, 2011·Annual Review of Immunology·Shane Crotty
Apr 5, 2011·European Urology·Marko BabjukUNKNOWN European Association of Urology (EAU)
Jun 28, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M Raza Zaidi, Glenn Merlino
Mar 2, 2012·The Journal of Clinical Investigation·Antonio Sica, Alberto Mantovani
Jun 8, 2012·Science Translational Medicine·Claire BiotMatthew L Albert
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
May 15, 2013·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·John B Mumm, Martin Oft
Sep 26, 2013·Mucosal Immunology·M A Ingersoll, M L Albert
Jan 13, 2015·Cancer Letters·Matthew R DavisYujiang Fang

❮ Previous
Next ❯

Citations

Jun 10, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tony W NgSteven A Porcelli
Feb 15, 2019·Frontiers in Immunology·Ezio T FokMusa M Mhlanga
Jun 18, 2021·Frontiers in Cell and Developmental Biology·Zhenyu NieShufang Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.